Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018160704) ANTI-TIGIT ANTIBODIES
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/160704 International Application No.: PCT/US2018/020239
Publication Date: 07.09.2018 International Filing Date: 28.02.2018
Chapter 2 Demand Filed: 20.12.2018
IPC:
A61K 39/00 (2006.01) ,A61K 39/395 (2006.01) ,A61P 35/00 (2006.01) ,C07K 14/47 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435
from animals; from humans
46
from vertebrates
47
from mammals
Applicants:
ADIMAB LLC [US/US]; 7 Lucent Drive Lebanon, New Hampshire 03766, US
Inventors:
PIASECKI, Julia C.; US
BEERS, Courtney; US
PETERSON, Scott; US
PRINZ, Bianka; US
Agent:
FLANAGAN, Lisa Dornbach; US
SNYDER, Joseph R.; US
ZYLSTRA, Eric J.; US
Priority Data:
62/464,52928.02.2017US
62/616,77912.01.2018US
Title (EN) ANTI-TIGIT ANTIBODIES
(FR) ANTICORPS ANTI-TIGIT
Abstract:
(EN) Isolated antibodies or antigen-binding portions that bind to human TIGIT (T- cell immunoreceptor with Ig and ITIM domains) are provided. In some embodiments, the antibody or antigen-binding portion thereof has a binding affinity (KD) for human TIGIT of less than 5 nM. In some embodiments, the anti-TIGIT antibody blocks binding of CD 155 and/or CD112 to TIGIT.
(FR) L'invention concerne des anticorps isolés ou des parties de liaison à l'antigène qui se lient au TIGIT (immunorécepteur des lymphocytes T avec des domaines Ig et ITIM) humain. Dans certains modes de réalisation, l'anticorps ou la partie de liaison à l'antigène de celui-ci a une affinité de liaison (KD) pour le TIGIT humain inférieure à 5 nM. Dans certains modes de réalisation, l'anticorps anti-TIGIT bloque la liaison de CD 155 et/ou de CD112 à TIGIT.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)